Actively Recruiting
Chronic Thromboembolic Disease: A Prospective Registry
Led by University of California, San Francisco · Updated on 2025-06-12
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying patients with chronic thromboembolic disease (CTD) and chronic thromboembolic pulmonary hypertension (CTEPH) to understand the natural history of these conditions. This observational registry aims to learn about long-term outcomes after various treatments, including medications, balloon pulmonary angioplasty, and pulmonary endarterectomy. It also evaluates how these treatments affect patients' quality of life and ability to exercise. Participants include patients diagnosed with CTED or CTEPH, who have undergone medical, surgical, or interventional treatments. These patients will be followed over an average of five years, during which their health status and quality of life will be assessed through chart reviews and patient surveys. The study collects data on survival, exercise tolerance, oxygen use, functional class, and other quality of life measures. During the study, participants will complete health quality questionnaires and have their medical records reviewed regularly. Researchers will monitor changes in exercise capacity, oxygen use, New York Heart Association functional class, and patient-reported scores such as the European Quality of Life Five Dimension (EQ-5D) and emPHasis-10. The study also tracks lung transplantation events and the use of specific medications and procedures. This long-term follow-up provides valuable insights into disease progression and treatment impact over time.
CONDITIONS
Brief Title
Chronic Thromboembolic Disease Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with chronic thromboembolic disease (CTED) and/or chronic thromboembolic pulmonary hypertension (CTEPH) as defined by specific pulmonary pressure and resistance measurements or exercise limitations
- Radiologic evidence of chronic thromboembolic disease by imaging tests
- Post-embolic exercise intolerance with chronic thromboembolic disease without resting pulmonary hypertension
- Treatment with anticoagulation for 3 months or more before diagnosis
- Age 18 years or older
You will not qualify if you...
- Pulmonary hypertension primarily caused by conditions other than World Health Organization group 4 (CTEPH)
- Refusal to participate in clinical research or receive interventions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 5 years
Participants with chronic thromboembolic disease or pulmonary hypertension are followed and given quality of life questionnaires to assess their health status over time.
Periodic assessments during the study duration
Trial Site Locations
Total: 1 location
1
University of California San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
M
Miles Conrad, MD
X
Xiao Wu, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here